Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• COVID-AntibodyIndependent statistical analysis of Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04334876).Phase NAResults postedn = 571NCT04334876
• COViNOXIndependent statistical analysis of A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 191NCT04421508
• COVIPACT 2Independent statistical analysis of Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 29NCT04747249
• CoVPN 3006A detailed statistical analysis of CoVPN 3006, a randomized phase 3 crossover study evaluating Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease through the Month 4 study visit.Phase 3Results postedn = 1,923NCT04811664
• Cranberry Effect on Urinary Tract Infections: Complete Statistical AnalysisIndependent statistical analysis of Cranberry Effect on Urinary Tract Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02996981).Phase NAResults postedn = 167NCT02996981
• CROSSIndependent statistical analysis of Cesarean Trial of Staples vs. Sutures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01211600).Phase NAResults postedn = 746NCT01211600
• Cross-vaccination Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.: Complete Statistical AnalysisIndependent statistical analysis of Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.: primary endpoint results,…Phase 3Results postedn = 8,687NCT02690207
• CROWN CORONAIndependent statistical analysis of the randomized phase 3 CROWN CORONA trial evaluating M-M-R II vaccine versus placebo for prevention of symptomatic COVID-19, including Bayesian logistic regression, risk differences, confidence intervals, p-values, and…Phase 3Results postedn = 3,411NCT04333732
• CROWN CORONAIndependent statistical analysis of CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04333732).Phase 3Results postedn = 3,411NCT04333732
• CRUSHIndependent statistical analysis of Connecting Resources for Urban Sexual Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02183909).Phase NAResults postedn = 378NCT02183909
• CSISP-MENC1Independent statistical analysis of Immunogenicity of the Booster Dose of Two MenC Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00392808).Phase 4Results postedn = 389NCT00392808
• CTS-1027 in Interferon-Naive Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of CTS-1027 in Interferon-Naive Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00925990).Phase 2Results postedn = 70NCT00925990
• CTSI-PLACEIndependent statistical analysis of A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 87NCT02597790
• Culturally Tailored HPV Psychoeducational Multimedia Intervention: Complete Statistical AnalysisIndependent statistical analysis of Culturally Tailored HPV Psychoeducational Multimedia Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06098690).Phase NAResults postedn = 63NCT06098690
• Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 9NCT00949117
• D Mannose in Recurrent Urinary Tract Infections: Complete Statistical AnalysisIndependent statistical analysis of D Mannose in Recurrent Urinary Tract Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01808755).Phase 3Results postedn = 60NCT01808755
• DAHHS-2Independent statistical analysis of Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 80NCT02600325
• Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: Complete Statistical AnalysisIndependent statistical analysis of Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 1,354NCT00080119
• DAR-PIAIndependent statistical analysis of DAR-901 TB Booster Vaccine to Prevent TB in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02712424).Phase 2Results postedn = 625NCT02712424
• DARE-CIndependent statistical analysis of DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01743521).Phase 4Results postedn = 14NCT01743521
• Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics: Complete Statistical AnalysisIndependent statistical analysis of Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 16NCT02759861
• Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate): Complete Statistical AnalysisIndependent statistical analysis of Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 57NCT04048382
• Development of Childhood Anti-Influenza Immunity: Complete Statistical AnalysisIndependent statistical analysis of Development of Childhood Anti-Influenza Immunity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03673345).Phase 4Results postedn = 125NCT03673345
• DFA-02 in Patients Undergoing Colorectal Surgery: Complete Statistical AnalysisIndependent statistical analysis of DFA-02 in Patients Undergoing Colorectal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01496352).Phase 1/2Results postedn = 30NCT01496352
• Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: Complete Statistical AnalysisIndependent statistical analysis of Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 891NCT00913380
• Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults: Complete Statistical AnalysisIndependent statistical analysis of Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 40NCT03413735
• Digital Interventions to Treat Hazardous Drinking: Complete Statistical AnalysisIndependent statistical analysis of Digital Interventions to Treat Hazardous Drinking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04890652).Phase NAResults postedn = 33NCT04890652
• DISCOVERIndependent statistical analysis of the DISCOVER phase 3 trial evaluating F/TAF versus F/TDF for HIV-1 pre-exposure prophylaxis, including non-inferiority testing, rate-ratio analysis, BMD, renal biomarkers, and statistical methodology.Phase 3Results postedn = 5,399NCT02842086
• Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 6NCT00625729
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 14NCT01093586
• Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 12NCT00295880
• Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock: Complete Statistical AnalysisIndependent statistical analysis of Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 252NCT00604019
• DORAVIPEPIndependent statistical analysis of Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study: primary endpoint results, effect…Phase 4Results postedn = 399NCT04233372
• Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019): Complete Statistical AnalysisIndependent statistical analysis of Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 35NCT04233216
• Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 741NCT01018030
• Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI): Complete Statistical AnalysisIndependent statistical analysis of Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI): primary endpoint results,…Phase 2Results postedn = 17NCT03298048
• Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]: Complete Statistical AnalysisIndependent statistical analysis of Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]: primary endpoint results, effect estimate with…Phase 2Results postedn = 161NCT04564547
• Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections: Complete Statistical AnalysisIndependent statistical analysis of Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 126NCT02045797
• Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients: Complete Statistical AnalysisIndependent statistical analysis of Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 64NCT01054729
• Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 180NCT00434512
• Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 400NCT00223990
• DOXY-PEPIndependent statistical analysis of Doxy-Post-exposure Prophylaxis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05853120).Phase 4Results postedn = 45NCT05853120
• DPARTIndependent statistical analysis of Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04487145).Phase 4Results postedn = 194NCT04487145
• dPEP-KEIndependent statistical analysis of Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 449NCT04050540
• Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate: Complete Statistical AnalysisIndependent statistical analysis of Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 56NCT01523002
• Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients: Complete Statistical AnalysisIndependent statistical analysis of Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01227395).Phase NAResults postedn = 476NCT01227395
• DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury: Complete Statistical AnalysisIndependent statistical analysis of DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 2NCT04447404
• Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose: Complete Statistical AnalysisIndependent statistical analysis of Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 698NCT01543087
• DYADIndependent statistical analysis of Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 222NCT04585737
• E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 1NCT04015336

← All therapeutic areas